Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-05-18
2009-10-20
Tsang, Cecilia (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07605132
ABSTRACT:
Peptide factors isolated from skin following exposure to chemical or thermal injury and treatment with iodine preparations are capable of reducing or ameliorating the extent of injury when administered to other animals. Specific peptides, including fragments of histone H2A and fibrinopeptide A, and preferred derivatives of these peptides are disclosed. Pharmaceutical compositions and methods of using these peptides are also disclosed. The extracts, peptides and pharmaceutical compositions according to the invention are useful for the prevention and treatment of inflammatory conditions and exposure to noxious stimuli.
REFERENCES:
patent: 4215109 (1980-07-01), Ruhenstroth-Bauer et al.
patent: 5300501 (1994-04-01), Porter et al.
patent: 5776892 (1998-07-01), Counts et al.
patent: 6468537 (2002-10-01), Datta et al.
patent: 6673623 (2004-01-01), Huberman
patent: 2003/0007964 (2003-01-01), Bae et al.
patent: 2004/0039157 (2004-02-01), Staton et al.
patent: 2004/0224077 (2004-11-01), Kochhar et al.
patent: 27 50 290 (1979-05-01), None
patent: 27 50 920 (1979-05-01), None
patent: 0 489 577 (1992-06-01), None
patent: 1 297 753 (2003-04-01), None
patent: WO 98/09985 (1998-03-01), None
patent: WO 01/38522 (2001-05-01), None
patent: WO 03/017920 (2003-03-01), None
Ashcroft et al., “Therapeutic strategies for psoriasis,” Journal of Clinical Pharmacy and Therapeutics (2000) 25: 1-10.
Citron, “Alzheimer's disease: treatments in discovery and development,” Nature Neuroscience Supplement (2002) 5: 1055-1057.
Coussens et al., “Inflammation and cancer,” Nature (2002) 420: 860-867.
Elgjo et al., “Proliferation-dependent effect of skin extracts (Chalone) on mouse epidermal cell flux at the G1-S, S-G2and G2-M transitions,” Virchows Arch [Cell Pathol] (1983) 42: 143-151.
Korczyn et al., “Emerging therapies in the pharmacological treatment of Parkinson's disease,” Drugs (2002) 62(5): 775-786.
Masuda et al., “Human fibrinopeptide A mediates allergic reaction in mice in the acute phase,” Peptides (2001) 22: 1511-1513.
Myers et al., “Collagen-induced arthritis, an animal model of autoimmunity,” Life Sciences (1997) 61(19): 1861-1878.
Rizzello et al., “The management of refractory Crohn's disease,” Ailment Pharmacol Ther (2002) 16(4): 40-47.
Scherer et al., “The effect of fibrinopeptides A and B on experimental allergic encephalomyelitis,” Clin. exp. Immunol. (1980) 40: 49-59.
Skuk et al., “Experimental and therapeutic approaches to muscular dystrophies,” Current Opinion in Neurology (2002) 15: 563-569.
Steinman et al., “How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis,” Ann Neurol (2006) 60: 12-21.
Wiendl et al., “Therapeutic approaches in multiple sclerosis,” Biodrugs (2002) 16(3): 183-200.
Bradley Christina
Tsang Cecilia
Winston & Strawn LLP
Yissum Research Development Company of the Hebrew University of
LandOfFree
Protective factors against inflammation, burns and noxious... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protective factors against inflammation, burns and noxious..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protective factors against inflammation, burns and noxious... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4083879